Volastra Therapeutics

Executive Summary

Volastra Therapeutics is a preclinical-stage oncology company pioneering a novel approach to cancer treatment by targeting chromosomal instability (CIN), a hallmark of aggressive and metastatic tumors. Founded in 2020 and headquartered in New York, the company has raised $60 million to develop therapies that exploit synthetic lethal vulnerabilities in cancer cells with high CIN. Unlike traditional therapies, Volastra's platform aims to selectively eliminate tumor cells while sparing healthy tissue, offering a potential breakthrough for treatment-resistant cancers. The company's lead programs focus on inhibiting mitotic checkpoint proteins such as KIF18A and PLK4, which are essential for survival of CIN-high cells, positioning Volastra as a leader in this emerging therapeutic space.

Upcoming Catalysts (preview)

• Q2 2026Preclinical proof-of-concept data for lead KIF18A inhibitor at major oncology conference (e.g., AACR 2026)80% success
• Q1 2027IND filing for first-in-class CIN-targeting therapy40% success
• H2 2026Series C financing round to support Phase I clinical trial initiation70% success